
|Articles|October 15, 2003
AAO makes case for OPT for Medicare patients
Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
What ‘I’m Fine’ Really Means: An Open Letter from a Thyroid Eye Disease (TED) Patient
2
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
3
Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease
4
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
5


















































.png)


